CA Patent

CA2727927A1 — Pharmacokinetics of iontophoretic sumatriptan administration

Assigned to Teva Pharmaceuticals International GmbH · Expires 2009-12-23 · 16y expired

What this patent protects

Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

USPTO Abstract

Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.

Drugs covered by this patent

sumatriptan-succinate (SUMATRIPTAN SUCCINATE)

Patent Metadata

Patent number: CA2727927A1
Jurisdiction: CA
Classification: —
Expires: 2009-12-23
Drug substance claim: No
Drug product claim: No
Assignee: Teva Pharmaceuticals International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.